| Previous Close | 141.03 |
| Open | 142.01 |
| Bid | 140.77 x 300 |
| Ask | 141.15 x 100 |
| Day's Range | 138.05 - 142.95 |
| 52 Week Range | 68.50 - 192.94 |
| Volume | 581,667 |
| Avg. Volume | 1,160,246 |
| Market Cap | 7.56B |
| Beta | 2.36 |
| PE Ratio (TTM) | -16.47 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Capital Cube•4 hours ago
TESARO, Inc. breached its 50 day moving average in a Bearish Manner : TSRO-US : June 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
- Motley Fool•2 days ago
How Things Look for Opko Health, Inc. in 3 Charts
It hasn't been a great year so far for Opko Health, but the future could be brighter.
- Investor's Business Daily•8 days ago
Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.?
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
